{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:41:11Z","timestamp":1792806071085,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04405-6","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T04:35:24Z","timestamp":1779597324000},"page":"4996-5009","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Practical integration of ctDNA-defined minimal residual disease in gastrointestinal cancers: testing windows and evidence-aligned management frameworks"],"prefix":"10.1007","volume":"28","author":[{"given":"Nan","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuzhou","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9738-2038","authenticated-orcid":false,"given":"Jun","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"issue":"1","key":"4405_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","volume":"159","author":"M Arnold","year":"2020","unstructured":"Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159(1):335-349.e15. https:\/\/doi.org\/10.1053\/j.gastro.2020.02.068.","journal-title":"Gastroenterology"},{"issue":"3","key":"4405_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"4405_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.763790","volume":"11","author":"Y Peng","year":"2021","unstructured":"Peng Y, Mei W, Ma K, Zeng C. Circulating tumor DNA and minimal residual disease (MRD) in solid tumors: current horizons and future perspectives. Front Oncol. 2021;11:763790. https:\/\/doi.org\/10.3389\/fonc.2021.763790.","journal-title":"Front Oncol"},{"issue":"13","key":"4405_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132432","volume":"16","author":"K Turabi","year":"2024","unstructured":"Turabi K, Klute K, Radhakrishnan P. Decoding the dynamics of circulating tumor DNA in liquid biopsies. Cancers (Basel). 2024;16(13):2432. https:\/\/doi.org\/10.3390\/cancers16132432.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"4405_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cells14030161","volume":"14","author":"O Abidoye","year":"2025","unstructured":"Abidoye O, Ahn DH, Borad MJ, Wu C, Bekaii-Saab T, Chakrabarti S, et al. Circulating tumor DNA testing for minimal residual disease and its application in colorectal cancer. Cells. 2025;14(3):161. https:\/\/doi.org\/10.3390\/cells14030161.","journal-title":"Cells"},{"issue":"346","key":"4405_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92. https:\/\/doi.org\/10.1126\/scitranslmed.aaf6219.","journal-title":"Sci Transl Med"},{"issue":"8","key":"4405_CR7","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5(8):1124\u201331. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0528.","journal-title":"JAMA Oncol"},{"issue":"8","key":"4405_CR8","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1001\/jamaoncol.2019.0512","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang Y, Li L, Cohen JD, Kinde I, Ptak J, Popoli M, et al. Prognostic potential of circulating tumor DNA measurement in postoperative surveillance of nonmetastatic colorectal cancer. JAMA Oncol. 2019;5(8):1118\u201323. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0512.","journal-title":"JAMA Oncol"},{"issue":"24","key":"4405_CR9","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261\u201372. https:\/\/doi.org\/10.1056\/NEJMoa2200075.","journal-title":"N Engl J Med"},{"issue":"11","key":"4405_CR10","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1200\/OP.24.00167","volume":"20","author":"F Battaglin","year":"2024","unstructured":"Battaglin F, Lenz HJ. Clinical applications of circulating tumor DNA profiling in GI cancers. JCO Oncol Pract. 2024;20(11):1481\u201390. https:\/\/doi.org\/10.1200\/OP.24.00167.","journal-title":"JCO Oncol Pract"},{"issue":"5","key":"4405_CR11","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie J, Wang Y, Lo SN, Lahouel K, Cohen JD, Wong R, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat Med. 2025;31(5):1509\u201318. https:\/\/doi.org\/10.1038\/s41591-025-03579-w.","journal-title":"Nat Med"},{"issue":"1","key":"4405_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023;29(1):127\u201334. https:\/\/doi.org\/10.1038\/s41591-022-02115-4.","journal-title":"Nat Med"},{"issue":"1","key":"4405_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.clcc.2022.12.001","volume":"22","author":"S Sato","year":"2023","unstructured":"Sato S, Nakamura Y, Oki E, Yoshino T. Molecular residual disease-guided adjuvant treatment in resected colorectal cancer: focus on CIRCULATE-Japan. Clin Colorectal Cancer. 2023;22(1):53\u20138. https:\/\/doi.org\/10.1016\/j.clcc.2022.12.001.","journal-title":"Clin Colorectal Cancer"},{"issue":"3 Suppl","key":"4405_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1200\/JCO.2024.42.3_suppl.9","volume":"42","author":"PM Kasi","year":"2024","unstructured":"Kasi PM, Aushev VN, Ensor J, et al. Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II\/III colorectal cancer (CRC): interim analysis of BESPOKE CRC study. J Clin Oncol. 2024;42(3 Suppl):9. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.9.","journal-title":"J Clin Oncol"},{"issue":"7655","key":"4405_CR15","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446\u201351. https:\/\/doi.org\/10.1038\/nature22364.","journal-title":"Nature"},{"issue":"2","key":"4405_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4143\/crt.2022.1026","volume":"55","author":"H Kim","year":"2023","unstructured":"Kim H, Park KU. Clinical circulating tumor DNA testing for precision oncology. Cancer Res Treat. 2023;55(2):351\u201366. https:\/\/doi.org\/10.4143\/crt.2022.1026.","journal-title":"Cancer Res Treat"},{"key":"4405_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1055968","volume":"12","author":"HT Chan","year":"2023","unstructured":"Chan HT, Nagayama S, Otaki M, Chin YM, Fukunaga Y, Ueno M, et al. Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients. Front Oncol. 2023;12:1055968. https:\/\/doi.org\/10.3389\/fonc.2022.1055968.","journal-title":"Front Oncol"},{"issue":"3","key":"4405_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.annonc.2024.12.006","volume":"36","author":"B Mart\u00ednez-Castedo","year":"2025","unstructured":"Mart\u00ednez-Castedo B, Camblor DG, Mart\u00edn-Arana J, Carbonell-Asins JA, Garc\u00eda-Mic\u00f3 B, Gambardella V, et al. Minimal residual disease in colorectal cancer: tumor-informed versus tumor-agnostic approaches\u2014unraveling the optimal strategy. Ann Oncol. 2025;36(3):263\u201376. https:\/\/doi.org\/10.1016\/j.annonc.2024.12.006.","journal-title":"Ann Oncol"},{"issue":"18","key":"4405_CR19","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1182\/blood.2022018825","volume":"141","author":"C Vlasschaert","year":"2023","unstructured":"Vlasschaert C, Mack T, Heimlich JB, Niroula A, Uddin MM, Weinstock J, et al. A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic data sets. Blood. 2023;141(18):2214\u201323. https:\/\/doi.org\/10.1182\/blood.2022018825.","journal-title":"Blood"},{"issue":"3","key":"4405_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70185","volume":"18","author":"AG Hadd","year":"2025","unstructured":"Hadd AG, Silvestro A, McKelvey BA, Baden J, Bormann Chung C, et al. Establishing a common lexicon for circulating tumor DNA analysis and molecular residual disease: insights from the BLOODPAC consortium. Clin Transl Sci. 2025;18(3):e70185. https:\/\/doi.org\/10.1111\/cts.70185.","journal-title":"Clin Transl Sci"},{"issue":"10","key":"4405_CR21","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.7049","volume":"22","author":"BA Caughey","year":"2024","unstructured":"Caughey BA, Parikh AR. ctDNA\/MRD testing for colon cancer: a work in progress or ready for prime-time standard of care? J Natl Compr Canc Netw. 2024;22(10):e247049. https:\/\/doi.org\/10.6004\/jnccn.2024.7049.","journal-title":"J Natl Compr Canc Netw"},{"key":"4405_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100068","volume":"4","author":"C Soueidy","year":"2024","unstructured":"Soueidy C, Zaanan A, Gelli M, Taieb J. Clinical impact of circulating tumor DNA to track minimal residual disease in colorectal cancer patients: hopes and limitations. ESMO Gastrointest Oncol. 2024;4:100068. https:\/\/doi.org\/10.1016\/j.esmogo.2024.100068.","journal-title":"ESMO Gastrointest Oncol"},{"key":"4405_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-04073-y","author":"AU Khan","year":"2025","unstructured":"Khan AU, Jasim YH, Shahid K, Saidov J, Atamuratova Z, Urazbaeva D. Circulating tumor DNA as a predictive biomarker for colorectal cancer postsurgical recurrence: a systematic review and meta-analysis. Clin Transl Oncol. 2025. https:\/\/doi.org\/10.1007\/s12094-025-04073-y.","journal-title":"Clin Transl Oncol"},{"issue":"12","key":"4405_CR24","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1038\/s41591-025-04030-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie J, Wang Y, Loree JM, Cohen JD, Wong R, Price T, et al. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial. Nat Med. 2025;31(12):4291\u2013300. https:\/\/doi.org\/10.1038\/s41591-025-04030-w.","journal-title":"Nat Med"},{"issue":"4 Suppl","key":"4405_CR25","doi-asserted-by":"publisher","first-page":"LBA22","DOI":"10.1200\/JCO.2025.43.4_suppl.LBA22","volume":"43","author":"H Bando","year":"2025","unstructured":"Bando H, et al. The ALTAIR study: trifluridine\/tipiracil versus placebo in patients with molecular residual disease following curative resection of colorectal cancer. J Clin Oncol. 2025;43(4 Suppl):LBA22. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.LBA22.","journal-title":"J Clin Oncol"},{"issue":"3 Suppl","key":"4405_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1200\/JCO.2024.42.3_suppl.27","volume":"42","author":"G Maddalena","year":"2024","unstructured":"Maddalena G, Dasari A, Parikh AR, Kopetz S, Overman MJ, You YN, et al. INTERCEPT program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): results from a prospective clinical cohort. J Clin Oncol. 2024;42(3 Suppl):27. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.27.","journal-title":"J Clin Oncol"},{"key":"4405_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114159","volume":"207","author":"N Verschoor","year":"2024","unstructured":"Verschoor N, Bos MK, HoopOomen-de E, Martens JWM, Sleijfer S, Jager A, et al. A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: the importance of trial design. Eur J Cancer. 2024;207:114159. https:\/\/doi.org\/10.1016\/j.ejca.2024.114159.","journal-title":"Eur J Cancer"},{"issue":"23","key":"4405_CR28","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1200\/JCO.23.02301","volume":"42","author":"D Stetson","year":"2024","unstructured":"Stetson D, Labrousse P, Russell H, Shera D, Abbosh C, Dougherty B, et al. Next-generation molecular residual disease assays: do we have the tools to evaluate them properly? J Clin Oncol. 2024;42(23):2736\u201340. https:\/\/doi.org\/10.1200\/JCO.23.02301.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4405_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaoncol.2025.5144","volume":"12","author":"GQ Zhang","year":"2026","unstructured":"Zhang GQ, Meyerhardt JA, Shi Q, Twombly T, Pederson L, Ma C, et al. Predictive role of circulating tumor DNA in stage III colon cancer treated with celecoxib: a post hoc analysis of the CALGB (Alliance)\/SWOG 80702 phase 3 randomized clinical trial. JAMA Oncol. 2026;12(2):149\u201358. https:\/\/doi.org\/10.1001\/jamaoncol.2025.5144.","journal-title":"JAMA Oncol"},{"issue":"1","key":"4405_CR30","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.221529","volume":"307","author":"VS Jayaprakasam","year":"2023","unstructured":"Jayaprakasam VS, Alvarez J, Omer DM, Gollub MJ, Smith JJ, Petkovska I. Watch-and-wait approach to rectal cancer: the role of imaging. Radiology. 2023;307(1):e221529. https:\/\/doi.org\/10.1148\/radiol.221529.","journal-title":"Radiology"},{"issue":"4","key":"4405_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3393\/ac.2023.00269.0038","volume":"39","author":"SH Lee","year":"2023","unstructured":"Lee SH. Total neoadjuvant therapy for rectal cancer: evidence and challenge. Ann Coloproctol. 2023;39(4):301\u20136. https:\/\/doi.org\/10.3393\/ac.2023.00269.0038.","journal-title":"Ann Coloproctol"},{"issue":"8","key":"4405_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003741","volume":"18","author":"Y Wang","year":"2021","unstructured":"Wang Y, Yang L, Bao H, Fan X, Xia F, Wan J, et al. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: a prospective cohort study. PLoS Med. 2021;18(8):e1003741. https:\/\/doi.org\/10.1371\/journal.pmed.1003741.","journal-title":"PLoS Med"},{"issue":"5","key":"4405_CR33","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41416-020-0941-4","volume":"123","author":"S Murahashi","year":"2020","unstructured":"Murahashi S, Akiyoshi T, Sano T, Fukunaga Y, Noda T, Ueno M, et al. Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. Br J Cancer. 2020;123(5):803\u201310. https:\/\/doi.org\/10.1038\/s41416-020-0941-4.","journal-title":"Br J Cancer"},{"key":"4405_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105548","volume":"112","author":"J Zhou","year":"2025","unstructured":"Zhou J, Li L, Liu Y, Jia W, Liu Q, Gao X, et al. Circulating tumour DNA in predicting and monitoring survival of patients with locally advanced rectal cancer undergoing multimodal treatment: long-term results from a prospective multicenter study. EBioMedicine. 2025;112:105548. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105548.","journal-title":"EBioMedicine"},{"key":"4405_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-80855-8","volume":"14","author":"C Molinari","year":"2024","unstructured":"Molinari C, Marisi G, Laliotis G, Spickard E, Rapposelli IG, Petracci E, et al. Assessment of circulating tumor DNA in patients with locally advanced rectal cancer treated with neoadjuvant therapy. Sci Rep. 2024;14:29536. https:\/\/doi.org\/10.1038\/s41598-024-80855-8.","journal-title":"Sci Rep"},{"key":"4405_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00521-5","volume":"11","author":"PS Pezeshki","year":"2023","unstructured":"Pezeshki PS, Ghalehtaki R. The clinical application of ctDNA to predict response to neoadjuvant chemoradiotherapy in patients with locally-advanced rectal cancer. Biomark Res. 2023;11:81. https:\/\/doi.org\/10.1186\/s40364-023-00521-5.","journal-title":"Biomark Res"},{"issue":"12","key":"4405_CR37","doi-asserted-by":"publisher","first-page":"e1198","DOI":"10.1093\/oncolo\/oyad151","volume":"28","author":"L Chang","year":"2023","unstructured":"Chang L, Zhang X, He L, Ma Q, Fang T, Jiang C, et al. Prognostic value of ctDNA detection in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Oncologist. 2023;28(12):e1198\u2013208. https:\/\/doi.org\/10.1093\/oncolo\/oyad151.","journal-title":"Oncologist"},{"issue":"24","key":"4405_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16244173","volume":"16","author":"T M\u00f6gele","year":"2024","unstructured":"M\u00f6gele T, H\u00f6ck M, Sommer F, Friedrich L, Sommer S, Schmutz M, et al. Circulating tumor DNA for prediction of complete pathological response to neoadjuvant radiochemotherapy in locally advanced rectal cancer (NEORECT trial). Cancers (Basel). 2024;16(24):4173. https:\/\/doi.org\/10.3390\/cancers16244173.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"4405_CR39","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1158\/1078-0432.CCR-20-4769","volume":"27","author":"J Vidal","year":"2021","unstructured":"Vidal J, Casadevall D, Bellosillo B, Pericay C, Garcia-Carbonero R, Losa F, et al. Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: a biomarker study from the GEMCAD 1402 trial. Clin Cancer Res. 2021;27(10):2890\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4769.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4405_CR40","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1093\/oncolo\/oyad336","volume":"29","author":"SL Alden","year":"2024","unstructured":"Alden SL, Lee V, Narang AK, Meyer J, Gearhart SL, Christenson ES. Circulating tumor DNA to predict radiographic and pathologic response to total neoadjuvant therapy in locally advanced rectal cancer. Oncologist. 2024;29(3):e414\u20138. https:\/\/doi.org\/10.1093\/oncolo\/oyad336.","journal-title":"Oncologist"},{"issue":"3 Suppl","key":"4405_CR41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JCO.2024.42.3_suppl.12","volume":"42","author":"J Tie","year":"2024","unstructured":"Tie J, Wang Y, Loree JM, Cohen JD, Wong R, Price T, et al. Circulating tumor DNA analysis informing adjuvant chemotherapy in locally advanced rectal cancer: the randomized AGITG DYNAMIC-Rectal study. J Clin Oncol. 2024;42(3 Suppl):12. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.12.","journal-title":"J Clin Oncol"},{"issue":"21","key":"4405_CR42","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","volume":"390","author":"M Chalabi","year":"2024","unstructured":"Chalabi M, Verschoor YL, Tan PB, Balduzzi S, Van Lent AU, Grootscholten C, et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N Engl J Med. 2024;390(21):1949\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2400634.","journal-title":"N Engl J Med"},{"issue":"4","key":"4405_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70017","volume":"16","author":"J Li","year":"2025","unstructured":"Li J, Wu C, Song Y, Fan Y, Li C, Li H, et al. Exploring the clinical value of perioperative ctDNA-based detection of molecular residual disease in patients with esophageal squamous cell carcinoma. Thorac Cancer. 2025;16(4):e70017. https:\/\/doi.org\/10.1111\/1759-7714.70017.","journal-title":"Thorac Cancer"},{"issue":"1","key":"4405_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s44276-025-00158-x","volume":"3","author":"Q Hu","year":"2025","unstructured":"Hu Q, Kimura Y, Ikeda S, Tanaka Y, Nakanoko T, Ota M, et al. Circulating tumor DNA monitoring detects minimal residual disease and predicts outcomes in patients with esophageal adenocarcinoma or squamous cell carcinoma after esophagectomy. BJC Rep. 2025;3(1):52. https:\/\/doi.org\/10.1038\/s44276-025-00158-x.","journal-title":"BJC Rep"},{"key":"4405_CR45","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00420","volume":"6","author":"BM Huffman","year":"2022","unstructured":"Huffman BM, Aushev VN, Budde GL, Chao J, Dayyani F, Hanna D, et al. Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers. JCO Precis Oncol. 2022;6:e2200420. https:\/\/doi.org\/10.1200\/PO.22.00420.","journal-title":"JCO Precis Oncol"},{"key":"4405_CR46","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00288","volume":"8","author":"EM Lander","year":"2024","unstructured":"Lander EM, Aushev VN, Huffman BM, Hanna D, Dutta P, Ferguson J, et al. Circulating tumor DNA as a prognostic biomarker for recurrence in patients with locoregional esophagogastric cancers with a pathologic complete response. JCO Precis Oncol. 2024;8:e2400288. https:\/\/doi.org\/10.1200\/PO.24.00288.","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"4405_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102334","volume":"6","author":"Z Liu","year":"2025","unstructured":"Liu Z, Wang G, Yang Y, Su Y, Zhang H, Liu J, et al. ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma. Cell Rep Med. 2025;6(9):102334. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102334.","journal-title":"Cell Rep Med"},{"key":"4405_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01220","volume":"10","author":"J Jiang","year":"2020","unstructured":"Jiang J, Ye S, Xu Y, Chang L, Hu X, Ru G, et al. Circulating tumor DNA as a potential marker to detect minimal residual disease and predict recurrence in pancreatic cancer. Front Oncol. 2020;10:1220. https:\/\/doi.org\/10.3389\/fonc.2020.01220.","journal-title":"Front Oncol"},{"issue":"5","key":"4405_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13051124","volume":"13","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Esmail A, Hassanain H, Dhillon V, Abdelrahim W, Al-Najjar E, et al. Correlative analysis of tumor-informed circulating tumor DNA (ctDNA) and the survival outcomes of patients with pancreatic adenocarcinoma. Biomedicines. 2025;13(5):1124. https:\/\/doi.org\/10.3390\/biomedicines13051124.","journal-title":"Biomedicines"},{"key":"4405_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-76903-y","volume":"14","author":"C Maulat","year":"2024","unstructured":"Maulat C, Canivet C, Cabarrou B, Pradines A, Selves J, Casanova A, et al. Prognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adenocarcinoma patients. Sci Rep. 2024;14:27296. https:\/\/doi.org\/10.1038\/s41598-024-76903-y.","journal-title":"Sci Rep"},{"issue":"10","key":"4405_CR51","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v16.i10.107875","volume":"16","author":"MF Teixeira","year":"2025","unstructured":"Teixeira MF, BoradSerrano Uson MPL. Circulating tumor DNA in biliary tract cancers: a review of current applications. World J Clin Oncol. 2025;16(10):107875. https:\/\/doi.org\/10.5306\/wjco.v16.i10.107875.","journal-title":"World J Clin Oncol"},{"key":"4405_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1616064","volume":"13","author":"Y Wang","year":"2025","unstructured":"Wang Y, Li Y, Liang Z, Zhang Y, Li T, Tian C, et al. Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives. Front Cell Dev Biol. 2025;13:1616064. https:\/\/doi.org\/10.3389\/fcell.2025.1616064.","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"4405_CR53","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1111\/cas.14926","volume":"112","author":"H Taniguchi","year":"2021","unstructured":"Taniguchi H, Nakamura Y, Kotani D, Yukami H, Mishima S, Sawada K, et al. CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 2021;112(7):2915\u201320. https:\/\/doi.org\/10.1111\/cas.14926.","journal-title":"Cancer Sci"},{"key":"4405_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102999","volume":"139","author":"A Holz","year":"2025","unstructured":"Holz A, Paul B, Zapf A, Pantel K, Joosse SA. Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: a systematic review and meta-analysis. Cancer Treat Rev. 2025;139:102999. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102999.","journal-title":"Cancer Treat Rev"},{"issue":"22","key":"4405_CR55","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1158\/1078-0432.CCR-23-0079","volume":"29","author":"G Patelli","year":"2023","unstructured":"Patelli G, Mauri G, Tosi F, Amatu A, Bencardino K, Bonazzina E, et al. Circulating tumor DNA to drive treatment in metastatic colorectal cancer. Clin Cancer Res. 2023;29(22):4530\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0079.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"4405_CR56","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","volume":"28","author":"A Sartore-Bianchi","year":"2022","unstructured":"Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022;28(8):1612\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01886-0.","journal-title":"Nat Med"},{"issue":"4","key":"4405_CR57","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.5635","volume":"7","author":"D Ciardiello","year":"2024","unstructured":"Ciardiello D, Martinelli E, Troiani T, Mauri G, Rossini D, Martini G, et al. Anti-EGFR rechallenge in patients with refractory ctDNA RAS\/BRAF wt metastatic colorectal cancer: a nonrandomized controlled trial. JAMA Netw Open. 2024;7(4):e245635. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.5635.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"4405_CR58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.annonc.2025.10.008","volume":"37","author":"C Cann","year":"2026","unstructured":"Cann C, Eng C. Positioning EGFR re-treatment in modern metastatic colorectal cancer: insights from PARERE. Ann Oncol. 2026;37(1):3\u20135. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.008.","journal-title":"Ann Oncol"},{"issue":"15","key":"4405_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152520","volume":"17","author":"N Vojjala","year":"2025","unstructured":"Vojjala N, Gibatova V, Shah RN, Singal S, Prabhu R, Krishnamoorthy G, et al. Integrating circulating tumor DNA into clinical management of colorectal cancer: practical implications and therapeutic challenges. Cancers (Basel). 2025;17(15):2520. https:\/\/doi.org\/10.3390\/cancers17152520.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"4405_CR60","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","volume":"35","author":"MA Gouda","year":"2024","unstructured":"Gouda MA, Janku F, Wahida A, Buschhorn L, Schneeweiss A, Abdel Karim N, et al. Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST). Ann Oncol. 2024;35(3):267\u201375. https:\/\/doi.org\/10.1016\/j.annonc.2023.12.007.","journal-title":"Ann Oncol"},{"issue":"11","key":"4405_CR61","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1097\/DCR.0000000000003491","volume":"67","author":"SS Krishnamurthi","year":"2024","unstructured":"Krishnamurthi SS. Expert commentary on ctDNA testing for minimal residual disease assessment and surveillance. Dis Colon Rectum. 2024;67(11):1366\u20137. https:\/\/doi.org\/10.1097\/DCR.0000000000003491.","journal-title":"Dis Colon Rectum"},{"key":"4405_CR62","unstructured":"U.S. Food and Drug Administration. Use of circulating tumor deoxyribonucleic acid for early-stage solid tumor drug development: guidance for industry. 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-circulating-tumor-deoxyribonucleic-acid-early-stage-solid-tumor-drug-development-guidance. Accessed 4 Mar 2026."},{"issue":"5","key":"4405_CR63","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.1270","volume":"5","author":"Y Li","year":"2024","unstructured":"Li Y, Heer AK, Sloane HS, Edelstein DL, Tie J, Gibbs P, et al. Budget impact analysis of circulating tumor DNA testing for colon cancer in commercial health and medicare advantage plans. JAMA Health Forum. 2024;5(5):e241270. https:\/\/doi.org\/10.1001\/jamahealthforum.2024.1270.","journal-title":"JAMA Health Forum"},{"key":"4405_CR64","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251384238","volume":"17","author":"H Wang","year":"2025","unstructured":"Wang H, Kramer A, Greuter MJE, Rubio-Alarc\u00f3n C, Lissenberg-Witte B, Meijer GA, et al. ctDNA-guided de-escalation of adjuvant chemotherapy in stage III colon cancer: early model-based evaluation of cost-effectiveness. Ther Adv Med Oncol. 2025;17:17588359251384238. https:\/\/doi.org\/10.1177\/17588359251384238.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"4405_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005344","volume":"11","author":"PJ Vellanki","year":"2023","unstructured":"Vellanki PJ, Ghosh S, Pathak A, Fusco MJ, Bloomquist EW, Tang S, et al. Regulatory implications of ctDNA in immuno-oncology for solid tumors. J Immunother Cancer. 2023;11(2):e005344. https:\/\/doi.org\/10.1136\/jitc-2022-005344.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"4405_CR66","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1200\/OP-24-00481","volume":"20","author":"K DeCarli","year":"2024","unstructured":"DeCarli K, Bradbury A, Lopez AM, Camacho P, Chatwal MS, Friese CR, et al. Ethical and clinical considerations in ordering and responding to molecular diagnostics and circulating tumor DNA as the science evolves. JCO Oncol Pract. 2024;20(11):1508\u201314. https:\/\/doi.org\/10.1200\/OP-24-00481.","journal-title":"JCO Oncol Pract"},{"key":"4405_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00984-9","volume":"9","author":"AE Boukouris","year":"2025","unstructured":"Boukouris AE, Michaelidou K, Joosse SA, Charpidou A, Mavroudis D, Syrigos KN, et al. A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced Non-Small Cell Lung Cancer. npj Precis Oncol. 2025;9:178. https:\/\/doi.org\/10.1038\/s41698-025-00984-9.","journal-title":"npj Precis Oncol"},{"key":"4405_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14746-0","volume":"25","author":"Y Cha","year":"2025","unstructured":"Cha Y, Cho SH, Park EY, Lee DE, Park T, Choi MK, et al. Platform study of circulating tumor DNA directed adjuvant chemotherapy in colon cancer (CLAUDIA colon cancer, KCSG CO22-12). BMC Cancer. 2025;25:1373. https:\/\/doi.org\/10.1186\/s12885-025-14746-0.","journal-title":"BMC Cancer"},{"key":"4405_CR69","unstructured":"NRG Oncology. Testing ctDNA as a biomarker for adjuvant therapy intensity in stage III colon cancer (NRG-GI008, \u201cCIRCULATE-NORTH AMERICA\u201d study). 2025. https:\/\/www.nrgoncology.org\/Home\/News\/Post\/testing-ctdna-as-a-biomarker-for-adjuvant-therapy-intensity-in-stage-3-colon-cancer-nrg-gi008-the-circulate-us-study\/. Accessed 4 Mar 2026."},{"issue":"10","key":"4405_CR70","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.ccell.2025.09.006","volume":"43","author":"WHA Tsui","year":"2025","unstructured":"Tsui WHA, Jiang P, Lo YMD. Cell-free DNA fragmentomics in cancer. Cancer Cell. 2025;43(10):1792\u2013814. https:\/\/doi.org\/10.1016\/j.ccell.2025.09.006.","journal-title":"Cancer Cell"},{"issue":"11","key":"4405_CR71","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1002\/1878-0261.13643","volume":"18","author":"G Zhao","year":"2024","unstructured":"Zhao G, Jiang R, Shi Y, Gao S, Wang D, Li Z, et al. Circulating cell-free DNA methylation-based multi-omics analysis allows early diagnosis of Pancreatic Ductal Adenocarcinoma. Mol Oncol. 2024;18(11):2801\u201313. https:\/\/doi.org\/10.1002\/1878-0261.13643.","journal-title":"Mol Oncol"},{"issue":"12","key":"4405_CR72","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1002\/1878-0261.70116","volume":"19","author":"M Lapin","year":"2025","unstructured":"Lapin M, Tjensvoll K, Edland KH, Oltedal S, Garresori H, Gilje B, et al. Tumor-agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell-free DNA fragmentomics. Mol Oncol. 2025;19(12):3535\u201347. https:\/\/doi.org\/10.1002\/1878-0261.70116.","journal-title":"Mol Oncol"},{"key":"4405_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61890-z","volume":"16","author":"J Wu","year":"2025","unstructured":"Wu J, Xu X, Zhang Q, Li P, Wu T, Guo S, et al. Cell-free DNA testing for the detection and prognosis prediction of pancreatic cancer. Nat Commun. 2025;16:6645. https:\/\/doi.org\/10.1038\/s41467-025-61890-z.","journal-title":"Nat Commun"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04405-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04405-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04405-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:02:12Z","timestamp":1792803732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04405-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":73,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["4405"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04405-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,24]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Institutional review board statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}